• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

An Appraisal of Using Opioids in Patients with Opioid Use Disorder
J Am Podiatr Med Assoc. 2023 May-Jun;113(3):22-150. doi: 10.7547/22-150.ABSTRACTPodiatric physicians have come to realize that opioid use disorder (OUD) is a public health crisis causing morbidity, mortality, lost productivity, and legal cost in the United States. Opioid analgesics are efficient first-line pain relievers for acute and chronic lower-extremity pain syndrome. Perioperative pain management strategies have been proposed using opioid stewardship, but there are few standardized protocols to guide podiatric medical providers treating patients with OUD. First, we describe the pharmacology of therapeutic agents used...
Source: Journal of the American Podiatric Medical Association - July 18, 2023 Category: Podiatry Authors: Robert G Smith Source Type: research

Illicitly Manufactured Fentanyl-Involved Overdose Deaths with Detected Xylazine - United States, January 2019-June 2022
This report uses data from CDC's State Unintentional Drug Overdose Reporting System (SUDORS) to describe IMF-involved§ overdose deaths with and without xylazine detected that occurred during January 2019-June 2022. Among 21 jurisdictions, which included 20 states and the District of Columbia, the monthly percentage of IMF-involved deaths with xylazine detected increased 276%, from 2.9% to 10.9%. Among IMF-involved deaths during January 2021-June 2022 in 32 jurisdictions, xylazine was detected in a higher percentage of jurisdictions in the Northeast U.S. Census Bureau region; listing detected xylazine as a cause of death v...
Source: MMWR Morb Mortal Wkl... - June 29, 2023 Category: Epidemiology Authors: Mbabazi Kariisa Julie O'Donnell Sagar Kumar Christine L Mattson Bruce A Goldberger Source Type: research

Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature
CONCLUSIONS: SSPs can successfully refer participants to SUD treatment and deliver onsite buprenorphine treatment. Future studies should explore strategies to optimize the implementation of onsite buprenorphine. Because linkage rates were suboptimal for methadone, offering onsite methadone treatment at SSPs may be an appealing solution, but would require changes in federal regulations. In tandem with continuing to develop onsite treatment capacity, funding should support evidence-based linkage interventions and increasing accessibility, availability, affordability and acceptability of SUD treatment programs.PMID:37301953 |...
Source: Addiction Science and Clinical Practice - June 10, 2023 Category: Addiction Authors: Andrea Jakubowski Sabrina Fowler Aaron D Fox Source Type: research

Pages: 1  2  3  4  5  6  7  8  9